Biomarkers and osteoarthritis


Book Section

© 2019 Elsevier Inc. All rights reserved. For personalized medicine approaches to be adopted for the treatment of osteoarthritis (OA), there will need to be a reconciliation of two important aspects of medical care-the focus on the individual and the need for cost-effectiveness. The focus on the individual is likely to be most cost-effective during the very early stages of OA, before substantial structural changes have arisen, and when the disease is likely to be most amenable to modification. Biomarkers will be central to identification of the early stages of this disease to make possible the implementation of personalized medicine treatment approaches to ward off the recalcitrant, disabling, and more costly late stages of the disease.

Full Text

Duke Authors

Cited Authors

  • Kraus, VB; Hsueh, MF

Published Date

  • January 1, 2019

Book Title

  • Genomic and Precision Medicine: Infectious and Inflammatory Disease

Start / End Page

  • 429 - 444

International Standard Book Number 13 (ISBN-13)

  • 9780128014967

Digital Object Identifier (DOI)

  • 10.1016/B978-0-12-801496-7.00022-8

Citation Source

  • Scopus